London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Company now needs a major player to scale this breakthrough tech. The likes of Halma,Stryker,S&N could all quickly scale Steriwave now its gaining universal recognition and increased adoption. Consultants lead change and Steriwave is changing HAI post surgery. No brainer.
Obviously still loss making and cash flow negative
Reason more funding required
Last results minuscule revenues from the hospitals already using Stetiwave
Positive news - escalation of uptake - price falls. Bizarre.
So what revenues are being made from these deployments ?
Only a matter of time
Ross also highlighted Ondine's commercial momentum, including the deployment of Steriwave in eight new healthcare facilities and a growing international presence, now spanning 22 facilities in Canada and expanding in the UK and Spain.
The success is attributed partly to Steriwave's effectiveness in reducing the need for antibiotics, as demonstrated in a UK study, and its alignment with antimicrobial resistance efforts. Ondine plans to continue expanding in European markets, capitalize on its success in Canada, and explore potential in the United States through FDA phase three trials.
Ondine is a gamechanger. I invested in Immupharma in Jan/Feb and posted multiple reasons to buy at 1.3p. It has doubled in under a month. Ondine is similarly undervalued It's technology is cutting edge and is now snowballing after years of proof of concept and first-mover adoption.
Reducing antibiotic use is the single biggest driver in global Healthcare as we are unprepared for the next (inevitable) pandemic. Steriwave goes a long way to helping resolve Hospital acquired infections and it's multiple potential applications are being addressed. I can see many major companies being interested in picking up this tiddler before it flies above the radar.
"Surgical site infections are devastating. If you look at a surgical site infection in a total joint replacement, it’s a months-long recovery process,” says Dr. Andrew Glennie, a QEII orthopaedic surgeon and clinical champion for the Steriwave “test-and-try" in Canada.
Steriwave is currently trialing in NHS.
The 3 sell trades at 10p just before the close were my buys. Can someone explain how I was offered a price so different to the other buys that occurred around the same time.
If you are wondering why I made 3 trades: after the first trade, I decided it was worth buying more and then just before the close, I wondered if I could repeat my good fortune and since I could, I bought some more.
45 trades today. I think this share is still so under the radar it's unreal.
From X.....
Ondine Biomedical
@OndineBio
·
Mar 18
"It is a no-brainer for us and the nurses are very excited to be involved.”
Read about how the team at the #QEII Health Sciences Centre is using Ondine’s Steriwave technology. Special thanks to the
@QEIIFoundation
for funding this year-long study.
Ondine Biomedical Inc - Vancouver-based life sciences company - Announces significant commercial progress to date in 2024, ahead of management's expectations. Says Ondine's Steriwave technology is deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago. Two orthopedic surgeon group practices in the Toronto area will also shortly begin offering Steriwave to patients undergoing elective orthopedic procedures.
Current stock price: 9.64 pence, up 4.2% in London on Friday
I don't think that the true relevance of this contract has been evaluated by the investment community....yet.
NHS policy is used as a guide globally since it's decisions have major effects of its overall budget. This adoption of Steriwave after evaluation of a 6 month pilot was after a stringent cost/benefit analysis by one of its senior assessment authorities. The big point is that it's being used in orthopaedic pre-op which is a field change from the recent 77% reduction in HAI's in London oropharyngeal surgery.
Hi
Singer Capital Markets has today issued a short Company Update for OBI, which is a client. It describes the RNS as " very positive" on " a positive development" for the company. Singer has yet to revise its forecasts, recalculate its target price, or change its recommendation from "Buy".
Please note that Singer has yet to adjust OBI's number of shares in issue following the previous fundraise, and occasionally expresses figures actually in Sterling as CAD. In the absence of any estimate of the value for the NHS contract in Pontefract, Singer's Target Price should perhaps be treated as 56p, simply to take account of the 14% correction to the number of shares in issue (226mn versus 195mn).
let's hope that drives the SP up a tad more aggressively than we have seen so far.
Almas
BRIEF – Ondine Biomedical Says First Commercial Adoption Of Steriwave By NHS
07:57
March 25 (Reuters) – Ondine Biomedical Inc :
First Commercial Adoption Of Steriwave By Nhs
Source text for Eikon: ... Further company coverage:
(Reuters.Briefs@thomsonreuters.com;;)
Copyright 2024 Thomson Reuters. Click for restrictions.
RNS 13/12/23
"The Company has confirmed that it has more than doubled the number of Steriwave® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global emphasis on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine's photodisinfection technology."
Let's hope their discussions with all 75 hospitals are successful.
In terms of cash runway the RNS on 11/12/23 stated:
"The net proceeds from the Fundraising will provide further cash runway until at least mid Q2 2024. The Company continues to evaluate funding opportunities for its Phase 3 study in the US, subject to the finalisation of the trial design with the FDA, and for further commercial development internationally."
Question: will another fundraise be required?
The snowball is certainly gaining momentum as revenues will likely follow
First commercial adoption of Steriwave by the NHS
NHS deal gives patients access to groundbreaking
I have been following this for more than a year and made a first investment today of 45k shares (shown as a sell on here). I will buy more if I could understand the financial side and likely revenue from the NHS and other hospitals adopting Steriwave. Research continues.
Looks like the snowball has started to roll down hill
Well, that is a perfect answer to the question I raised yesterday about the Pontefract trial.
This is a pivotal RNS and exactly what I suspected in my last post. This really does open the door for Steriwave adoption across the NHS. YHEC is one of the prime influences within the NHS and acts as a first mover in many cases of national rollout. Excellent news that their pilot and subsequent appraisal has led to adoption. The cost savings if universally adopted across the NHS would be 'substantial' according to Ondine.
Sisyphus - thank you for your response.
As far as I can make out YHEC is undertaking an economic analysis based on results from primarily the Pontefract trial. I would expect conclusions from that are due any time. Since YHEC is an influencer for NHS policy it will look at savings that adoption of Steriwave could achieve. This could be quite a pivotal time for Ondine. Positive studies across the globe are accumulating.